No study has examined the combination
There is no in vitro, animal or human study of BPC-157 and TB-500 administered together.
PrecisePep/Blends & Stacks/Wolverine Stack
Regenerative Blend
Wolverine Stack
BPC-157 + TB-500 · the healing stack
Two peptides, two routes to repair — local vascular scaffolding and systemic cell mobilisation. The most widely used combination in the research community, and the one that stays running when the copper blends cycle off.
00 Overview
The Wolverine stack is the default injury combination in the research community and the one most people encounter first. The name is a comic-book reference to rapid healing, which tells you something about how it is marketed and nothing about what it does.
The rationale is genuinely the cleanest of any combination on this site: the two components solve different halves of the same problem. BPC-157 acts locally — it builds the vascular supply and signals resident fibroblasts at the injury. TB-500 acts systemically — it regulates actin and therefore the ability of repair cells to migrate to injury sites anywhere in the body. Infrastructure and logistics.
What the stack does not have is any evidence as a stack. Neither component has an adequately powered human musculoskeletal trial, and no study of any kind has combined them. Both are explicitly prohibited by WADA. Both are pro-angiogenic and pro-migratory, which is the mechanism and also the unresolved theoretical concern.
Its role in the cycling structure
In the widely circulated protocols, Wolverine is not primarily a standalone stack — it is the off-phase for KLOW. Rotating to it keeps BPC-157 and TB-500 continuous while giving copper exposure and melanocortin receptor activity a break. That is the most coherent piece of cycling logic in the community canon.
// Mechanism of action
BPC-157 — the local half. Upregulation of VEGFR2 and nitric oxide signalling drives angiogenesis at the injury site; reported FAK-paxillin pathway activity increases tendon fibroblast survival and migration; reported growth hormone receptor upregulation in tendon fibroblasts sensitises repairing tissue to endogenous anabolic signalling.
TB-500 — the systemic half. G-actin sequestration regulates the cytoskeletal remodelling that permits cell movement, mobilising endothelial cells and progenitor populations toward injury. Anti-fibrotic signalling reduces disordered scar formation.
Why they are described as complementary rather than redundant. Both promote angiogenesis, but by different routes and at different scales. BPC-157 builds vasculature where it is injected or where injury signals it; TB-500 supplies the migratory capacity to populate that vasculature from elsewhere. One is a construction crew, the other is the road network.
The shared caveat. Both mechanisms — new vessel growth and enhanced cell migration — are exactly what a tumour requires. This is stated on both component pages and it does not become less true when they are combined.
// What is in it
A blend is not a compound. It is several compounds sharing a vial, and each one carries its own evidence base, dose-response curve and risk profile. Study them individually before studying them together.
| Component | Share of blend | Role in the blend | Monograph link |
|---|---|---|---|
| BPC-157 Pentadecapeptide |
~5 mg of 10 (1:1) | Local repair. Angiogenesis via VEGFR2, nitric oxide signalling, fibroblast recruitment, tendon-to-bone healing, gut barrier restoration. | Monograph |
| TB-500 Thymosin β4 fragment |
~5 mg of 10 (1:1) | Systemic repair. Actin regulation driving cell migration to injury wherever it is, plus anti-fibrotic and remodelling signalling. | Monograph |
Blend arithmetic
The common presentation is a 10 mg total vial. Given that both components ship as 10 mg standalone vials, that implies a 1:1 split — 5 mg of each. Suppliers do not publish it, so treat it as a working assumption. At the 1 mg daily blend dose in the circulating protocols that is 500 mcg BPC-157 and 500 mcg TB-500 per day, and the vial lasts ten days.
That second figure is worth pausing on. 500 mcg of BPC-157 daily sits squarely in the community range, but 3.5 mg of TB-500 per week is well above the 2–2.5 mg twice-weekly loading figure most protocols use, and far above any maintenance figure. The blend format forces two very different dosing schedules into one, and this is what that costs.
The more meaningful distinction is that BPC-157 and TB-500 have very different half-lives and very different community dosing frequencies — BPC-157 daily or twice daily in micrograms, TB-500 twice weekly in milligrams. A fixed daily blend dose forces both onto the same schedule, which suits neither.
This is the strongest practical argument for dosing the two separately rather than buying a pre-blended vial.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Component evidence: BPC-157 tendon, ligament and gut healing in rodents [1]
Extensive rodent literature reporting accelerated and mechanically stronger healing, predominantly from a single research programme.
Component evidence: thymosin β4 anti-fibrotic and repair activity [2][3]
Animal cardiac, dermal and neurological repair data plus human topical ophthalmic trials for the full-length parent protein.
BPC-157 human safety signal from IBD development [1]
The compound was evaluated clinically as PL 14736 and described as safe in that setting. Small, and not for musculoskeletal use.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Complete local-plus-systemic repair coverage
The core rationale. Mechanistically the tidiest combination argument on this site — and still an argument rather than a result.
Faster recovery from acute soft-tissue injury
The dominant use case. Rodent tendon healing plus systemic cell mobilisation, extrapolated to a human with a torn hamstring.
Improvement in chronic tendinopathy
A harder claim than acute injury: chronic tendinopathy is a degenerative rather than inflammatory problem, and neither mechanism obviously addresses tendon matrix degeneration. Community non-response reports cluster here.
Myofascial pain and recovery in fibromyalgia
The musculoskeletal half of the argument made for KLOW, retained here without the KPV anti-inflammatory arm. It speaks to the concurrent myofascial pain many patients report rather than to central sensitisation, which is the primary pathology and which neither compound is proposed to touch.
PCOS — the rationale does not transfer to this blend
The PCOS case made for KLOW rests entirely on KPV and GHK-Cu, and Wolverine contains neither. This entry exists to say so plainly, because the two blends are frequently discussed interchangeably and share a name in the same protocols.
Reduced scar and adhesion formation
From the TB-500 anti-fibrotic literature. Whether it remodels established mature scar is a separate and unanswered question.
Gut healing alongside systemic repair
BPC-157 supplies the gut mechanism; TB-500 adds nothing specific here.
No cycling required
The community position, based on the absence of any identified receptor-desensitisation mechanism for either compound. Absence of an identified mechanism is not evidence that none exists — and it is not a safety argument for indefinite use of two pro-angiogenic peptides.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Meaningful pain reduction within 1–3 weeks
The dominant report, most often for elbow, shoulder, knee and Achilles complaints. Confounded by the natural history of soft-tissue injury and by any concurrent load management.
BPC-157 reported to act faster, TB-500 slower and broader
Consistent community distinction: local relief early from BPC-157, diffuse whole-body loosening over 2–4 weeks from TB-500. Matches the proposed mechanisms.
Improved range of motion
Attributed to the anti-fibrotic component.
Chronic issues improving around 8–9 months
A specific claim in the circulating protocol, presented as a reason to stay on continuously. There is no source for it and no mechanism proposed.
Less muscle ache and better recovery in fibromyalgia
Reported decreases in deep muscle ache and stiffness and improved tolerance of light exercise — the same reports attached to KLOW, which shares these two components. Uncontrolled, and in a condition whose symptoms fluctuate independently.
Non-response in degenerative problems
Common and under-posted. Users with structural degeneration — advanced arthritis, full-thickness tears — frequently report nothing.
Much less injection-site sting than KLOW
Consistently reported, and the practical reason the Wolverine phase is described as a relief.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination safety data
No study has assessed these two peptides administered together in any species.
Thymosin β4 expression associated with tumour progression [3]
Oncology literature links elevated Tβ4 expression to invasiveness and metastasis. An association in disease biology rather than a demonstration of causation from exogenous dosing, and the most relevant safety literature that exists for this stack.
No systemic human safety data for either compound
No pharmacokinetics, no chronic-dosing study, no long-term follow-up for either component by subcutaneous injection.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Two pro-angiogenic, pro-migratory agents in combination
The theoretical concern that applies to each component individually does not halve when they are combined. Nobody using this stack is screened for occult malignancy and no study has looked.
Indefinite continuous use
The "no cycling required" position means this stack is frequently run for many months without interruption — the longest cumulative exposure of any repair protocol, with the least data.
Product identity uncertainty for TB-500
Whether a vial contains the short fragment or full-length thymosin β4 varies by supplier, so the actual composition of a blend is often unknown.
Delaying effective treatment
Both fibromyalgia and PCOS have treatments with randomised evidence behind them. The practical risk of an unproven stack is not only what it does — it is the months spent not doing something that works.
Anti-fibrotic activity where fibrosis is structural
Scar tissue is sometimes load-bearing. A systemic anti-fibrotic signal does not distinguish adhesion from necessary repair.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Injection-site redness and small nodules
Generally mild; notably better tolerated than copper-containing blends.
Fatigue in the first days of TB-500 loading
One of the more consistent reports, typically at higher twice-weekly doses.
Head rush or lightheadedness after injection
Reported at larger doses, attributed to vasoactive effects.
Nothing at all
Non-response reports are common and under-represented.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Dose the two separately, not as a fixed blend
BPC-157 has a short systemic half-life and is dosed daily or twice daily; TB-500 is dosed twice weekly. A pre-blended fixed-ratio vial forces both onto one schedule, which fits the pharmacokinetics of neither. This is the strongest practical argument against buying the blend form.
Load through the proliferative phase, maintain through remodelling
Higher frequency early when cell migration and angiogenesis matter most, stepping down for the remodelling phase. Standard wound-healing reasoning applied to unstudied compounds.
Systemic administration is adequate
Both mechanisms are systemic. Injecting into or near a joint or tendon sheath adds infection and structural risk without a clear mechanistic gain.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Blend form: 1 mg total daily
The figure in the Gold Standard protocol — Wolverine blend at 1 mg for two vials as the KLOW off-phase.
Separate dosing, acute injury: BPC 500 mcg 2×/day + TB 2–2.5 mg 2×/week
The standard acute-injury "blast" schedule, typically for four to six weeks.
Separate dosing, maintenance: BPC 250 mcg daily + TB 2 mg weekly
The step-down phase.
Run continuously without cycling
The community position for both components. The longest-exposure practice on this site.
| Approach | BPC-157 | TB-500 | Duration |
|---|---|---|---|
| Acute injury blast | 500 mcg 2× daily | 2 – 2.5 mg 2× weekly | 4–6 weeks |
| Standard repair | 250–500 mcg daily | 2 mg weekly | 6–8 weeks |
| Maintenance | 250 mcg daily | 2 mg every 2 weeks | Ongoing |
| Pre-blended vial | Per ratio | Per ratio | 1 mg total daily |
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination studies exist
Neither pre-clinical nor clinical work has combined these compounds.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Internal synergy — local plus systemic
The reason the stack exists. Coherent, untested.
Wolverine as the KLOW off-phase
Continue repair signalling while copper and melanocortin exposure pause. The best-reasoned cycling structure in circulation.
Wolverine + GH secretagogues
The BPC-157 finding of increased GH receptor expression in tendon fibroblasts is the specific hook. Plausible; unstudied.
Wolverine alongside incretin-driven fat loss
Connective-tissue support and claimed GI tolerance during aggressive weight loss. No interaction data.
Adding GHK-Cu turns it into GLOW
The natural escalation, and the point at which copper exposure enters the picture.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The universal starting stack
Most people in the research community begin here before adding anything else.
Rotated with KLOW
Four vials KLOW, two vials Wolverine, repeat.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No protocol has been studied
No trial, animal study or registered protocol exists for the combination.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Pair with progressive mechanical loading
Tendon and ligament remodel along lines of applied stress. Repair signalling without a loading stimulus has no information about how to organise the tissue it builds. This is well established in rehabilitation literature independent of any peptide.
What actually sets the duration — and what does not
Worth separating the two components that drive this decision, because they point opposite ways. The peptide repair components are the argument for running long. BPC-157’s rodent literature is not confined to the injection site — intragastric and intraperitoneal dosing produce distant-organ effects, so it behaves systemically rather than as a local agent. And Tβ4 has the one published head-to-head on schedule: in rat chronic myocardial ischaemia, long-term dosing reduced infarct size and improved function where short-term dosing only trended that way. Human phase 1 work found no accumulation across repeated doses. What limits the course is the copper. GHK-Cu is the component with a cumulative-exposure rationale, and the rotation exists to let copper homeostasis normalise — not because BPC-157 or TB-500 have been shown to lose effect. No tachyphylaxis study exists for either peptide, so “no tolerance” remains an absence of evidence rather than a finding.
Time-limit the course
Given two pro-angiogenic compounds and no long-term data, a defined course with a defined endpoint carries less theoretical risk than indefinite use — regardless of the absence of a desensitisation mechanism.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Gold Standard Protocol — Wolverine at 1 mg for 2 vials between KLOW runs
The stated purpose is to let melanocortin receptors reset and copper homeostasis normalise while BPC-157 and TB-500 continue uninterrupted.
15-Compound Matrix — Q2 regenerative pillar
Grouped with KLOW in the regenerative and tissue repair category.
4–6 week acute blast, then maintenance
The general injury pattern outside the specific protocols above.
05b Condition-specific interest
This is the most-used injury stack in the grey market, and everything below inherits the same structural problem: two compounds, neither with a controlled human trial, combined in a ratio nobody has studied, for conditions neither has been tested in. The individual monographs carry the mechanism; this page is about what the combination does and does not add.
No approval, no trial
Neither component is approved anywhere, and the combination has never been studied as a combination in anything. Every argument for the pairing is additive reasoning — BPC-157 for repair signalling plus TB-500 for cell migration — rather than a demonstrated synergy. Two unproven compounds combined are not more proven than one; they are harder to attribute.
Theorized — the reason the blend exists
Tendon, ligament and acute soft-tissue injury
Pathophysiology
Tendon and ligament heal slowly because they are poorly vascularised, and repair depends on getting cells into the injury and sustaining them there. Both steps are rate-limiting.
Mechanistic rationale
The stack argument is that the two components attack different rate-limiting steps: BPC-157 driving angiogenesis and fibroblast outgrowth, TB-500 driving cell migration through actin sequestration. It is a coherent division of labour and it is entirely derived from separate rodent literatures. The combination has never been compared against either component alone in any species.
Community reports
Overwhelmingly the dominant reported use. Faster return to training is the near-universal claim, and it is unfalsifiable without a control — injuries heal, and people who feel better train sooner.
Components carrying the argument: BPC-157 angiogenesis + TB-500 cell migration
Theorized — and the interaction nobody checks
Post-surgical and post-operative recovery
Pathophysiology
Surgical healing follows the same phases as any wound, and is genuinely limited by perfusion, infection risk and mechanical loading during the vulnerable phase.
Mechanistic rationale
The repair rationale applies straightforwardly. What is rarely raised is that both components are pro-angiogenic, and surgeons care about that. Increased vascularity is desirable in some contexts and undesirable in others — haematoma risk, graft behaviour, and any procedure where the surgical plan assumes a particular healing rate. This is a conversation to have with the surgeon, not around them.
Community reports
Post-operative use is widely described, generally without the operating surgeon being told. Anticoagulation, wound checks and rehabilitation timelines are all set by someone working from an incomplete picture in that situation.
Components carrying the argument: Both components; angiogenesis is the shared property
Theorized — weaker, with a procedural risk
Osteoarthritis and chronic joint pain
Pathophysiology
Osteoarthritis pain arises from subchondral bone, synovium and capsule rather than from cartilage, which is aneural. Cartilage is also avascular, which limits what an angiogenic agent can reach.
Mechanistic rationale
The repair rationale is carried across from soft tissue rather than derived from joint work. The more important point is the delivery: intra-articular injection outside a clinical setting is the highest-risk practice documented on this site. A septic joint destroys cartilage within days and is a surgical emergency.
Community reports
Intra-articular use of this blend is discussed openly. Nothing here is a suggestion to do it; the entry exists so the specific consequence is stated rather than left out.
Components carrying the argument: Extrapolated repair signalling
Theorized — the premise does not hold
Fibromyalgia
Pathophysiology
Fibromyalgia is a disorder of central pain processing without demonstrable structural damage to muscle or connective tissue.
Mechanistic rationale
This blend is a tissue-repair stack. In a condition defined by the absence of a structural lesion, there is nothing for it to repair. Where it may help is a genuinely comorbid injury — a narrower claim, and the only version that survives scrutiny.
Community reports
Positive reports exist, as they do for nearly every intervention in fibromyalgia, a condition with a large placebo response and a fluctuating course.
Components carrying the argument: Peripheral repair — wrong compartment for a central disorder
Anecdotal — no mechanism reaches the endocrinology
PCOS
Pathophysiology
PCOS is driven by insulin resistance and hyperandrogenism. Neither is an injury, and neither is a repair problem.
Mechanistic rationale
No component of this blend acts on insulin sensitivity, ovarian steroidogenesis or gonadotrophin signalling. Where it appears in PCOS discussion it is on general anti-inflammatory framing, which is a long way from the pathophysiology.
Community reports
Sparse, and generally from people using it for something else who also have PCOS.
Components carrying the argument: None that reach the mechanism
| Condition | Does the mechanism fit? | Evidence | The thing to know |
|---|---|---|---|
| Tendon / ligament injury | Yes | Rodent, separate literatures | Never compared against either component alone |
| Post-surgical recovery | Yes | None | Tell the surgeon — both components are pro-angiogenic |
| Osteoarthritis | Partly | Extrapolated | Intra-articular injection risks a septic joint |
| Fibromyalgia | No | None | No structural lesion to repair |
| PCOS | No | None | Nothing here touches insulin or androgens |
What actually has evidence for these conditions
For tendinopathy and soft-tissue injury: progressive mechanical loading — heavy slow resistance or eccentric protocols sustained over months — has the best evidence of any intervention and outperforms every injectable it has been tested against. Load management, adequate protein and time do the rest. Corticosteroid injection buys short-term relief at the cost of worse long-term outcomes in several tendons.
For osteoarthritis: exercise therapy and weight reduction are first-line in every guideline, with topical and oral NSAIDs, physiotherapy, and joint replacement for end-stage disease.
For fibromyalgia: pregabalin, duloxetine and milnacipran are approved; graded exercise with cognitive behavioural therapy has the strongest evidence of any intervention.
For PCOS: metformin, combined hormonal contraceptives, letrozole for ovulation induction, inositol, and the GLP-1 agonists which now have randomised evidence in this population.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Available pre-blended (commonly 10–20 mg total per vial) or as two separate vials. Separate vials permit independent scheduling and are the better option for anyone who cares about matching each compound to its own pharmacokinetics.
Storage
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C.
Common vial sizes
Blend: most commonly 10 mg total, implying 5 mg of each. Separate: BPC-157 10 mg, TB-500 2-10 mg.
Stability notes
Neither component is unusually fragile. Sterility is the governing concern for daily multi-week use.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use. Neither component is approved anywhere. BPC-157 has been identified by the FDA as presenting significant safety risks for compounding use.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: component status: BPC-157 and TB-500 both recommended by PCAC, July 2026. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
Both components are explicitly prohibited by WADA — BPC-157 under S0 (non-approved substances) and thymosin β4 analogues under S2 (growth factors). TB-500 has featured in anti-doping enforcement actions. Prohibited at all times.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011.Review or meta-analysis
- PubMed: thymosin beta 4 — wound healing, angiogenesis and tissue repair (live query)Database or literature search
- PubMed: thymosin beta 4 expression, tumour progression and metastasis (live query)Database or literature search
- WADA Prohibited List (current edition)Regulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.